{
    "title": "Shot in the arm for Glaxo as trials of firm's new Covid-19 booster vaccine show encouraging results",
    "url": "https://www.dailymail.co.uk/money/markets/article-10912845/Glaxos-new-Covid-19-booster-vaccine-shows-positive-results-trials.html",
    "date": "2022-06-13",
    "keywords": [
        "booster",
        "covid19",
        "vaccine",
        "sanofi",
        "share",
        "fund",
        "glaxosmithkline",
        "group",
        "system",
        "response",
        "race",
        "jab",
        "money",
        "diy",
        "platform",
        "investment",
        "account",
        "fee",
        "dose",
        "news",
        "immune",
        "trialsthe",
        "jabhowever",
        "boost",
        "virus",
        "point",
        "vaccinesthe",
        "firm",
        "pfizer",
        "omicron",
        "variant",
        "combination",
        "emergence",
        "immunity",
        "need",
        "triomphe",
        "executive",
        "vice",
        "president",
        "divisionwe",
        "nextgeneration",
        "role",
        "health",
        "vaccination",
        "set",
        "iag",
        "boss",
        "recession",
        "pound",
        "storm",
        "clouds",
        "bitcoin",
        "crypto",
        "meltdown",
        "blaze",
        "packaging",
        "article",
        "capital",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing"
    ],
    "category": [
        "money",
        "markets"
    ]
}